{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-314994","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.363095+00:00","generated_at":"2026-05-16T13:31:47.249201+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunovant prices $550M stock offering; updates IMVT-1402 and batoclimab timelines","bullets":["Underwritten common stock offering of ~$550M gross proceeds; Roivant Sciences to purchase shares; expected close Dec 12, 2025.","Potentially registrational D2T RA trial of IMVT-1402: top-line results now expected in 2026 (previously initial open-label only in 2026).","Batoclimab Phase 3 TED studies: top-line results delayed to H1 2026 (previously by end of 2025); results shared concurrently.","Discussions commenced with HanAll to potentially return batoclimab rights; may result in dispute or arbitration.","Existing cash plus offering proceeds expected to fund operations through potential commercial launch of IMVT-1402 in Graves' Disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-314994","json":"https://secwatch.observer/filing/0001193125-25-314994.json","markdown":"https://secwatch.observer/filing/0001193125-25-314994.md","text":"https://secwatch.observer/filing/0001193125-25-314994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/0001193125-25-314994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:31:47.249201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}